University of Helsinki

News

• Dogs may provide an excellent model for understanding human complex diseases
  The new Swedish-Finnish study, published in Nature Genetics, indicates that the homogeneity of strong genetic risk factors within dog breeds makes dogs an excellent model to identify pathways involved in human complex diseases. (1.2.2010)
  
• A Finnish-Swiss team cracks the atomic structure of a major cancer drug target
  Researchers at the University of Helsinki, Finland, and the Paul Scherrer Institute (PSI) in Villigen, Switzerland, have determined the crystal structure of the ligand binding VEGF  receptor in complex with one of its ligands, VEGF-C. VEGFs and their receptors have been identified as major targets for drug development in cancer therapy. (20.1.2010)
• One attack is enough
  The heart fails and cholesterol kills. These two predicaments are all too familiar to Finns, and when medical treatment is used to prevent them, the most common methods are statins.(7.1.2010)
• Gene mismatch influences success of bone marrow transplants
  Missing gene in donor found to increase recipient’s chances of graft-versus-host disease, a common complication of bone marrow transplantation. (26.11.2009)
• Professor Leena Peltonen receives honorary title of Academician of Science
  Professor Leena Peltonen, MD, has been awarded the honorary title of Academician of Science. The letter of appointment was presented to Professor Peltonen by President of the Republic Tarja Halonen on 29 October 2009.(29.10.2009)
• New Master’s degree programme bridges the gap between the bedside and the lab
  Beginning in autumn 2010, the Faculty of Medicine at the University of Helsinki will be training not only doctors and dentist, but also Masters of Translational Medicine. The new Master’s programme will open up a connection between basic research and patient care. (27.10.2009)
  

News Archive>>

Current Science Issues

A Finnish-Swiss team cracks the atomic structure of a major cancer drug target

Researchers at the University of Helsinki, Finland, and the Paul Scherrer Institute (PSI) in Villigen, Switzerland, have determined the crystal structure of the ligand binding VEGF  receptor in complex with one of its ligands, VEGF-C. VEGFs and their receptors have been identified as major targets for drug development in cancer therapy.

Read more